CEO John Marotta was paid $10,371,414 in fiscal year 2025, ↑ up 1523.5% from fiscal year 2024, the 69th percentile of its disclosed peer group (SEC filing 0001140361-25-046064 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$10,371,414 ↑ John Marotta total, FY2025 | 69th CEO pay percentile vs peers | 178.8:1 CEO-to-median pay ratio | 96.29% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
AZTA's next annual pay disclosure, estimated November 22, 2026.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| John Marotta | $900,000 | $0 | $8,386,297 | $0 | $1,063,656 | $0 | $21,462 | $10,371,414 |
| President and Chief Executive Officer | ||||||||
| Lawrence Lin | 463,154 | 250,000 | 2,784,716 | 0 | 398,090 | 0 | 13,792 | 3,909,752 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Ephraim Starr | 191,077 | 0 | 2,142,271 | 0 | 143,705 | 0 | 5,187 | 2,482,240 |
| Senior Vice President, General Counsel and Corporate Secretary | ||||||||
| Jason Joseph | 355,615 | 0 | 1,388,088 | 0 | 321,246 | 0 | 205,753 | 2,270,703 |
| Former Senior Vice President, General Counsel and Corporate Secretary | ||||||||
| Olga Pirogova | 391,692 | 0 | 1,041,091 | 0 | 252,501 | 0 | 16,501 | 1,701,786 |
| Senior Vice President and Chief Human Resources Officer | ||||||||
| Ginger Zhou | 410,123 | 0 | 867,593 | 0 | 261,429 | 0 | 9,228 | 1,548,373 |
| Senior Vice President, President GENEWIZ | ||||||||
| Herman Cueto | 100,000 | 240,000 | 0 | 0 | 0 | 0 | 430,000 | 770,000 |
| Former Executive Vice President and Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| John Marotta | $10,371,414 | $638,811 | — | ↑ +9,732,603 |
| Lawrence Lin | 3,909,752 | — | — | — |
| Ephraim Starr | 2,482,240 | — | — | — |
| Jason Joseph | 2,270,703 | 2,408,144 | 1,444,170 | ↓ −137,441 |
| Olga Pirogova | 1,701,786 | 1,541,082 | 25,615 | ↑ +160,704 |
| Ginger Zhou | 1,548,373 | 1,573,935 | 849,019 | ↓ −25,562 |
| Herman Cueto | 770,000 | 3,566,008 | — | ↓ −2,796,008 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Azenta, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper AZTA reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the Azenta, Inc. Peer Teardown Report
$10,371,414 John Marotta total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of September 23, 2026 · Source: 0001140361-25-046064 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for AZTA
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order AZTA
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses AZTA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AZTA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the Azenta, Inc. Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Alan J. Malus | Independent Director | $286,998 |
| Dipal Doshi | Independent Director | $267,623 |
| Erica J. McLaughlin | Independent Director | $301,373 |
| Frank E. Casal | Chair of the Board | $404,765 |
| Martin Madaus | Independent Director | $295,123 |
| Quentin G. Koffey | Independent Director | $289,498 |
| Robyn C. Davis | Independent Director | $303,187 |
| Tina S. Nova | Independent Director | $293,248 |
| William L. Cornog | Independent Director | $288,873 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Robyn C. Davis | Director | 2026-02-05 | A | 5,663 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Erica J. McLaughlin | Director | 2026-02-05 | A | 5,663 | 28 | 157,715 | Common | Form 4 ↗ |
| Frank E. Casal | Director | 2026-02-05 | A | 7,243 | 28 | 201,718 | Common | Form 4 ↗ |
| Dipal Doshi | Director | 2026-02-05 | A | 5,663 | 28 | 157,715 | Common | Form 4 ↗ |
| Martin Madaus | Director | 2026-02-05 | A | 5,663 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William L. Cornog | Director | 2026-02-05 | A | 5,663 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Quentin G. Koffey | Director | 2026-02-05 | A | 5,663 | 0 | 0 | Common | Form 4 ↗ |
| Tina Susan Nova | Director | 2026-02-06 | A | 5,663 | 28 | 157,715 | Common | Form 4 ↗ |
| William E. Martin III | President Multiomics | 2026-04-28 | A | 17,790 | 24 | 431,230 | Common | Form 4 ↗ |
| Ephraim Starr | SVP, Gen Counsel & Secretary | 2026-05-15 | D | 3,621 | 16 | 58,008 | Common | Form 4 ↗ |
| William L. Cornog | Director | 2026-05-18 | A | 10,000 | 16 | 163,800 | Common | Form 4 ↗ |
| Ephraim Starr | SVP, Gen Counsel & Secretary | 2026-07-31 | A | 335 | 24 | 8,096 | Common | Form 4 ↗ |
| Olga Pirogova | SVP and CHRO | 2026-08-09 | D | 1,085 | 32 | 34,763 | Common | Form 4 ↗ |
| Ephraim Starr | SVP, Gen Counsel & Secretary | 2026-09-14 | A | 15,272 | 0 | 0 | Common | Form 4 ↗ |
| Lawrence Lin | EVP, CFO and Treasurer | 2026-09-14 | A | 30,544 | 0 | 0 | Common | Form 4 ↗ |
| Olga Pirogova | SVP and CHRO | 2026-09-14 | A | 15,272 | 0 | 0 | Common | Form 4 ↗ |
| William E. Martin III | President Multiomics | 2026-09-14 | A | 15,272 | 0 | 0 | Common | Form 4 ↗ |
| Martin Madaus | Interim CEO | 2026-09-14 | A | 36,653 | 0 | 0 | Common | Form 4 ↗ |
| Erik J. Bello | VP Chief Accounting Officer | 2026-09-15 | A | 4,586 | 0 | 0 | Common | Form 4 ↗ |
| Martin Madaus | Interim CEO | 2026-09-22 | D | 1,456 | 34 | 49,912 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| John Marotta | PSU | 2024-11-15 | 41,811 | 83,622 | — | 167,244 | $4,915,147 |
| Ginger Zhou | PSU | 2024-11-15 | 4,326 | 8,651 | — | 17,302 | 508,490 |
| Lawrence Lin | RSU | 2024-12-05 | — | — | 23,045 | — | 1,037,025 |
| Lawrence Lin | PSU | 2024-12-05 | 11,523 | 23,045 | — | 46,090 | 1,488,131 |
| Olga Pirogova | PSU | 2024-11-15 | 5,191 | 10,381 | — | 20,762 | 610,176 |
| Lawrence Lin | RSU | 2024-12-05 | — | — | 5,768 | — | 259,560 |
| Olga Pirogova | RSU | 2024-11-15 | — | — | 10,831 | — | 430,915 |
| Jason Joseph | PSU | 2024-11-15 | 6,921 | 13,841 | — | 27,682 | 813,549 |
| Jason Joseph | RSU | 2024-11-15 | — | — | 13,841 | — | 574,540 |
| Ginger Zhou | RSU | 2024-11-15 | — | — | 8,651 | — | 359,103 |
| John Marotta | RSU | 2024-11-15 | — | — | 83,622 | — | 3,471,149 |
| Ephraim Starr | RSU | 2025-05-15 | — | — | 37,779 | — | 1,009,077 |
| Ephraim Starr | PSU | 2025-05-15 | 18,890 | 37,779 | — | 75,558 | 1,133,194 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| John Marotta | $3,471,149 | $4,915,147 | $0 | 58.6% |
| Ginger Zhou | 359,103 | 508,490 | 0 | 58.6% |
| Lawrence Lin | 1,296,585 | 1,488,131 | 0 | 53.4% |
| Olga Pirogova | 430,915 | 610,176 | 0 | 58.6% |
| Jason Joseph | 574,540 | 813,549 | 0 | 58.6% |
| Ephraim Starr | 1,009,077 | 1,133,194 | 0 | 52.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Lawrence Lin | PSU | 23,045 | — | $949,684 |
| Lawrence Lin | RSU | 28,813 | — | 827,509 |
| John Marotta | PSU | 83,622 | — | 3,400,907 |
| Ephraim Starr | PSU | 37,779 | — | 1,218,373 |
| John Marotta | RSU | 83,622 | — | 2,401,624 |
| Ephraim Starr | RSU | 37,779 | — | 1,085,013 |
| Jason Joseph | PSU | 13,841 | — | 562,913 |
| Jason Joseph | PSU | 11,331 | — | 325,426 |
| Ginger Zhou | RSU | 629 | — | 18,065 |
| Jason Joseph | PSU | 16,493 | — | 473,679 |
| Olga Pirogova | PSU | 10,381 | — | 422,195 |
| Jason Joseph | RSU | 13,841 | — | 397,514 |
| Ginger Zhou | PSU | 8,651 | — | 351,836 |
| Olga Pirogova | RSU | 10,381 | — | 298,142 |
| John Marotta | PSU | 9,819 | — | 282,002 |
| Olga Pirogova | PSU | 9,621 | — | 276,315 |
| Olga Pirogova | RSU | 1,069 | — | 30,702 |
| Ginger Zhou | PSU | 9,621 | — | 276,315 |
| Ginger Zhou | RSU | 8,651 | — | 248,457 |
| Ginger Zhou | PSU | 5,666 | — | 162,728 |
| Jason Joseph | RSU | 3,665 | — | 105,259 |
| Olga Pirogova | RSU | 3,166 | — | 90,928 |
| John Marotta | RSU | 2,182 | — | 62,667 |
| Ginger Zhou | RSU | 3,166 | — | 90,928 |
| Jason Joseph | RSU | 1,259 | — | 36,158 |
| Ginger Zhou | RSU | 1,069 | — | 30,702 |
Azenta's executive compensation program is built on a pay-for-performance philosophy that rewards results, aligns leadership with shareholder interests, and supports sustainable value creation. The program emphasizes market alignment, a balanced pay structure of base salary, annual incentives, and long-term equity, and a significant portion of variable compensation tied to financial and strategic performance.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-01-28 | 38,413,005 | 1,479,264 | 37,724 | 96.29% | Passed |
| 2025 | 2025-01-30 | 40,649,757 | 228,004 | 511,173 | 99.44% | Passed |
| 2024 | 2024-01-30 | 49,109,585 | 900,374 | 123,893 | 98.2% | Passed |
| 2023 | 2023-01-31 | 59,630,140 | 756,469 | 35,855 | 98.75% | Passed |
| 2022 | 2022-01-24 | 65,645,925 | 440,161 | 121,150 | 99.33% | Passed |
| 2021 | 2021-01-26 | 66,268,061 | 254,028 | 39,450 | 99.62% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-01-28 | 96.29%a |
| 2025 | 2025-01-30 | 99.44%b |
| 2024 | 2024-01-30 | 98.2%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not have any effect on the results of those deliberations.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not have any effect on the results of those deliberations.”.
c. Approved under the standard stated in the filing — “Abstentions will have no effect on the results of the vote on Proposal No.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 178.8 : 1 |
|---|---|
| CEO total compensation | $10,371,414 |
| Median employee compensation | $57,992 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Frank E. CasalIndependent · Board Chair · Audit (Chair) · Nominating and Governance | $134,375 | $270,390 | — | — | — | $404,765 |
| Robyn C. DavisIndependent · Human Resources and Compensation (Chair) · Nominating and Governance | 91,814 | 211,373 | — | — | — | 303,187 |
| Erica J. McLaughlinIndependent · Audit · Environmental, Social and Governance | 90,000 | 211,373 | — | — | — | 301,373 |
| Martin MadausIndependent · Nominating and Governance | 83,750 | 211,373 | — | — | — | 295,123 |
| Tina NovaIndependent · ESG · Compensation · Human Capital · Environmental, Social and Governance | 81,875 | 211,373 | — | — | — | 293,248 |
| Tina S. NovaIndependent · Environmental, Social and Governance · Human Resources and Compensation | 81,875 | 211,373 | — | — | — | 293,248 |
| Quentin G. KoffeyIndependent · Human Resources and Compensation | 78,125 | 211,373 | — | — | — | 289,498 |
| William L. CornogIndependent · Value Creation (Chair) | 77,500 | 211,373 | — | — | — | 288,873 |
| Alan J. MalusIndependent · Human Resources and Compensation | 75,625 | 211,373 | — | — | — | 286,998 |
| Alan MalusIndependent · Compensation · Value Creation · Human Capital | 75,625 | 211,373 | — | — | — | 286,998 |
| Dipal DoshiIndependent · Audit · Environmental, Social and Governance | 56,250 | 211,373 | — | — | — | 267,623 |
| John P. MarottaEmployee director · Value Creation | — | — | — | — | — | 0 |
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | $215,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 18,250 / 12,500 |
| Stock ownership guideline | $300,000 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $926,814 |
| Equity awards (grant-date value) | $2,384,120 |
| All other compensation | $0 |
| Total cost of the board | $3,310,934 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Azenta, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Azenta, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Natera, Inc. | 2025 | Steven Chapman | $853,710 | $12,979,558 | $0 | $1,114,151 | $14,957,319 |
| 2 | Twist Bioscience Corporation | 2025 | Emily Leproust | 720,000 | 11,998,134 | 0 | 932,918 | 13,781,570 |
| 3 | Haemonetics Corporation | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 4 | Medpace Holdings, Inc. | 2025 | August Troendle | 937,417 | 0 | 9,999,999 | 0 | 11,443,766 |
| 5 | Azenta, Inc. | 2025 | John Marotta | 900,000 | 8,386,297 | 0 | 1,063,656 | 10,371,414 |
| 6 | Maravai LifeSciences Holdings Inc. | 2025 | Bernd Brust | 388,863 | 7,660,000 | 1,460,000 | 425,343 | 10,129,708 |
| 7 | Neogen Corporation | 2025 | Tony Zook | 601,539 | 3,999,997 | 3,998,235 | 513,400 | 9,127,092 |
| 8 | Neogen Corporation | 2026 | Mike Nassif | 630,769 | 3,250,000 | 3,250,000 | 1,000,000 | 8,693,916 |
| 9 | Guardant Health, Inc. | 2025 | AmirAli Talasaz | 1 | 8,647,709 | 0 | 0 | 8,661,227 |
| 10 | Bio-Techne Corporation | 2025 | Kim Kelderman | 936,000 | 3,929,942 | 1,932,848 | 1,318,917 | 8,151,181 |
| 11 | Veracyte, Inc. | 2025 | Marc Stapley | 700,000 | 5,890,877 | 0 | 826,000 | 7,421,877 |
| 12 | Tandem Diabetes Care, Inc. | 2025 | John Sheridan | 790,583 | 5,367,796 | 0 | 674,090 | 6,858,503 |
| 13 | Certara, Inc. | 2025 | William Feehery | 795,675 | 4,927,502 | 0 | 747,935 | 6,491,387 |
| 14 | 10x Genomics, Inc. | 2025 | Serge Saxonov | 674,250 | 5,020,269 | 0 | 634,725 | 6,329,244 |
| 15 | Fulgent Genetics, Inc. | 2025 | Ming Hsieh | 1,000,000 | 4,000,000 | 0 | 1,207,000 | 6,207,000 |
| 16 | Repligen Corporation | 2025 | Olivier Loeillot | 860,000 | 3,374,853 | 1,095,626 | 774,000 | 6,114,771 |
| 17 | NeoGenomics, Inc. | 2022 | David Woodhouse | 610,000 | 0 | 5,072,750 | 250,000 | 5,933,500 |
| 18 | Myriad Genetics, Inc. | 2025 | Samraat Raha | 856,901 | 3,989,729 | 0 | 814,660 | 5,686,740 |
| 19 | Cytek Biosciences, Inc. | 2025 | Wenbin Jiang | 620,000 | 2,000,000 | 2,000,000 | 485,211 | 5,120,061 |
| 20 | Cryoport, Inc. | 2025 | Jerrell Shelton | 967,845 | 192,300 | 306,869 | 908,510 | 2,375,524 |
| — | Sotera Health Company | — | — | — | — | — | — | not in coverage universe |
| — | Cytek Biosciences, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | MesaLabs, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Evotec SE | — | — | — | — | — | — | not in coverage universe |
| — | Veracyte, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Cryoport, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Azenta, Inc. | not disclosed | PSU 50 · RSU 50 | Yes — Relative TSR (rTSR) | Pearl Meyer |
| 10x Genomics, Inc. | 93% | PSU 60 · RSU 40 | Yes — 3-year Relative TSR | Alpine Rewards LLC |
| Bio-Techne Corporation | 128.1% | PSU 50 · Options 25 · RSU 25 | No | Aon |
| Certara, Inc. | 94% | PSU 60 · RSU 40 | Yes — annualized total stockholder return (ATSR) | Meridian Compensation Partners |
| Cryoport, Inc. | not disclosed | Option 61.5 · RSR 38.5 | not disclosed | Frederic W. Cook & Co., Inc. |
| Cryoport, Inc. | 92.2% | not disclosed | not disclosed | Frederic W. Cook & Co., Inc. |
| Cytek Biosciences, Inc. | 78.4% | RSU 50 · Options 50 | not disclosed | Meridian Compensation Partners, LLC |
| Cytek Biosciences, Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Meridian Compensation Partners, LLC |
| Evotec SE | not disclosed | not disclosed | not disclosed | not disclosed |
| Fulgent Genetics, Inc. | 120.7% | PSU 60 · RSU 40 | No | USI |
| Guardant Health, Inc. | 140% | PSU 50 · RSU 50 | No | Aon |
| Haemonetics Corporation | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| Maravai LifeSciences Holdings Inc. | not disclosed | not disclosed | No | Meridian Compensation Partners, LLC |
| Medpace Holdings, Inc. | 52.5% | Options 100 | not disclosed | Total Compensation Solutions (TCS) |
| MesaLabs, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Myriad Genetics, Inc. | 89% | RSU 50 · PSU 50 | Yes | Mercer, LLC |
| Natera, Inc. | 131.1% | PSU 50 · RSU 50 | No | Aon |
| Neogen Corporation | not disclosed | PSU 50 · Option 50 | not disclosed | Farient Advisors, LLC |
| Neogen Corporation | 60% | RSU 50 · Options 50 | not disclosed | WTW |
| NeoGenomics, Inc. | 75% | Option 100 | not disclosed | Aon |
| Repligen Corporation | 100% | RSU 50 · PSU 25 · Options 25 | No | Meridian Compensation Partners, LLC |
| Sotera Health Company | not disclosed | PSU 50 · RSU 50 · SAU 20 | not disclosed | Exequity |
| Tandem Diabetes Care, Inc. | 87% | PSU 50 · RSU 50 | Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027 | WTW |
| Twist Bioscience Corporation | 129.6% | PSU 50 · RSU 50 | No | not disclosed |
| Veracyte, Inc. | 118% | PSU 50 · RSU 50 | No | Aon |
| Veracyte, Inc. | not disclosed | RSU 50 · PSU 50 | not disclosed | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, John Marotta | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Summary Compensation Table” · page 44. As printed: 10,371,414. Filing ↗machine: r2 · c22 · span 1247118–1247129 |
| 2 | Section 01, Lawrence Lin | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Summary Compensation Table” · page 44. As printed: 3,909,752. Filing ↗machine: r5 · c22 · span 1259116–1259125 |
| 3 | Section 01, Ephraim Starr | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Summary Compensation Table” · page 44. As printed: 2,482,240. Filing ↗machine: r11 · c22 · span 1283000–1283009 |
| 4 | Section 01, Jason Joseph | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Summary Compensation Table” · page 44. As printed: 2,270,703. Filing ↗machine: r14 · c22 · span 1294848–1294857 |
| 5 | Section 01, Olga Pirogova | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Summary Compensation Table” · page 44. As printed: 1,701,786. Filing ↗machine: r17 · c22 · span 1307329–1307338 |
| 6 | Section 01, Ginger Zhou | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Summary Compensation Table” · page 44. As printed: 1,548,373. Filing ↗machine: r20 · c22 · span 1319485–1319494 |
| 7 | Section 01, Herman Cueto | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Summary Compensation Table” · page 44. As printed: 770,000. Filing ↗machine: r8 · c22 · span 1270955–1270962 |
| 8 | Section 03, John Marotta PSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r4 · c22 · span 1358630–1358636 |
| 9 | Section 03, Ginger Zhou PSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r20 · c22 · span 1431785–1431790 |
| 10 | Section 03, Lawrence Lin RSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r7 · c22 · span 1372110–1372116 |
| 11 | Section 03, Lawrence Lin PSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r7 · c22 · span 1372110–1372116 |
| 12 | Section 03, Olga Pirogova PSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r18 · c16 · span 1422053–1422059 |
| 13 | Section 03, Lawrence Lin RSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r8 · c22 · span 1376378–1376383 |
| 14 | Section 03, Olga Pirogova RSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r17 · c22 · span 1418146–1418152 |
| 15 | Section 03, Jason Joseph PSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r14 · c22 · span 1404028–1404034 |
| 16 | Section 03, Jason Joseph RSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r14 · c22 · span 1404028–1404034 |
| 17 | Section 03, Ginger Zhou RSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r20 · c22 · span 1431785–1431790 |
| 18 | Section 03, John Marotta RSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r4 · c22 · span 1358630–1358636 |
| 19 | Section 03, Ephraim Starr RSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r11 · c22 · span 1390503–1390509 |
| 20 | Section 03, Ephraim Starr PSU | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “Grants of Plan Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t226 · r11 · c22 · span 1390503–1390509 |
| 21 | Section 07, pay ratio | DEF 14A | 2025-12-18 | 0001140361-25-046064 | Section “CEO Pay Ratio”. As printed: 178.8 : 1. Filing ↗ |
| 22 | Section 08, Frank E. Casal | DEF 14A | 2025-12-19 | 0001140361-25-046158 | Section “Director Compensation”. As printed: 404,765. Filing ↗machine: span 653333–653509 |
| 23 | Section 08, Robyn C. Davis | DEF 14A | 2025-12-19 | 0001140361-25-046158 | Section “Director Compensation”. As printed: 303,187. Filing ↗machine: span 657459–657635 |
| 24 | Section 08, Erica J. McLaughlin | DEF 14A | 2025-12-19 | 0001140361-25-046158 | Section “Director Compensation”. As printed: 301,373. Filing ↗machine: span 667632–667808 |
| 25 | Section 08, Martin Madaus | DEF 14A | 2025-12-19 | 0001140361-25-046158 | Section “Director Compensation”. As printed: 295,123. Filing ↗machine: span 663505–663681 |
| 26 | Section 08, Tina Nova | DEF 14A | 2025-12-19 | 0001140361-25-046158 | Section “Director Compensation”. As printed: 293,248. Filing ↗machine: span 669734–669909 |
| 27 | Section 08, Tina S. Nova | DEF 14A | 2025-12-19 | 0001140361-25-046158 | Section “Director Compensation”. As printed: 293,248. Filing ↗machine: span 669734–669909 |
| 28 | Section 08, Quentin G. Koffey | DEF 14A | 2025-12-19 | 0001140361-25-046158 | Section “Director Compensation”. As printed: 289,498. Filing ↗machine: span 661568–661744 |
| 29 | Section 08, William L. Cornog | DEF 14A | 2025-12-19 | 0001140361-25-046158 | Section “Director Compensation”. As printed: 288,873. Filing ↗machine: span 655268–655444 |
| 30 | Section 08, Alan J. Malus | DEF 14A | 2025-12-19 | 0001140361-25-046158 | Section “Director Compensation”. As printed: 286,998. Filing ↗machine: span 665706–665882 |
| 31 | Section 08, Alan Malus | DEF 14A | 2025-12-19 | 0001140361-25-046158 | Section “Director Compensation”. As printed: 286,998. Filing ↗machine: span 665706–665882 |
| 32 | Section 08, Dipal Doshi | DEF 14A | 2025-12-19 | 0001140361-25-046158 | Section “Director Compensation”. As printed: 267,623. Filing ↗machine: span 659377–659553 |
| 33 | Section 08, John P. Marotta | DEF 14A | 2025-12-19 | 0001140361-25-046158 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 34 | Section 02, Robyn C. Davis 2026-02-05 | Form 4 | 2026-02-06 | 0001193125-26-041473 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Erica J. McLaughlin 2026-02-05 | Form 4 | 2026-02-06 | 0001193125-26-041476 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Frank E. Casal 2026-02-05 | Form 4 | 2026-02-06 | 0001193125-26-041478 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Dipal Doshi 2026-02-05 | Form 4 | 2026-02-06 | 0001193125-26-041482 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Martin Madaus 2026-02-05 | Form 4 | 2026-02-06 | 0001193125-26-041485 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, William L. Cornog 2026-02-05 | Form 4 | 2026-02-06 | 0001193125-26-041487 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Quentin G. Koffey 2026-02-05 | Form 4 | 2026-05-12 | 0001104659-26-059359 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Tina Susan Nova 2026-02-06 | Form 4 | 2026-02-06 | 0001193125-26-041527 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, William E. Martin III 2026-04-28 | Form 4 | 2026-04-30 | 0001949513-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Ephraim Starr 2026-05-15 | Form 4 | 2026-05-18 | 0002069816-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, William L. Cornog 2026-05-18 | Form 4 | 2026-05-19 | 0001193125-26-230764 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Ephraim Starr 2026-07-31 | Form 4 | 2026-08-04 | 0001628280-26-052799 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Olga Pirogova 2026-08-09 | Form 4 | 2026-08-11 | 0001628280-26-055760 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Ephraim Starr 2026-09-14 | Form 4 | 2026-09-16 | 0001628280-26-062343 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Lawrence Lin 2026-09-14 | Form 4 | 2026-09-16 | 0001628280-26-062344 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Olga Pirogova 2026-09-14 | Form 4 | 2026-09-16 | 0001628280-26-062345 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, William E. Martin III 2026-09-14 | Form 4 | 2026-09-16 | 0001628280-26-062348 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Martin Madaus 2026-09-14 | Form 4 | 2026-09-16 | 0001628280-26-062354 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Erik J. Bello 2026-09-15 | Form 4 | 2026-09-16 | 0001628280-26-062341 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Martin Madaus 2026-09-22 | Form 4 | 2026-09-23 | 0001628280-26-063164 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 06, 2026 vote | Form 8-K | 2026-01-29 | 0001437749-26-002409 | Item 5.07 · say-on-pay result. As reported: 96.29% (votes for as printed: 38,413,005). Filing ↗ |
| 55 | Section 06, 2025 vote | Form 8-K | 2025-02-05 | 0001437749-25-002824 | Item 5.07 · say-on-pay result. As reported: 99.44% (votes for as printed: 40,649,757). Filing ↗ |
| 56 | Section 06, 2024 vote | Form 8-K | 2024-02-01 | 0001558370-24-000691 | Item 5.07 · say-on-pay result. As reported: 98.2% (votes for as printed: 49,109,585). Filing ↗ |
| 57 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 58 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 59 | Section 09b board cost (computed) | Computed | — | — | Cash 926,814 + equity 2,384,120 + all other 0 = 3,310,934, summed across the director compensation table rows.machine: formula: Σ = 3,310,934 |
| 60 | Natera, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047770 | CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878 |
| 61 | Twist Bioscience Corporation, Section 10b CEO total | DEF 14A | 2026-01-06 | 0001581280-26-000006 | CEO total compensation as printed in Twist Bioscience Corporation's own proxy. As printed: 13,781,570. Filing ↗machine: t34 · r2 · c15 · span 1510951–1510961 |
| 62 | Haemonetics Corporation, Section 10b CEO total | DEF 14A | 2026-06-09 | 0000313143-26-000074 | CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. Filing ↗machine: span 718173–718183 |
| 63 | Medpace Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001668397-26-000012 | CEO total compensation as printed in Medpace Holdings, Inc.'s own proxy. As printed: 11,443,766. Filing ↗machine: t43 · r3 · c9 · span 495770–495781 |
| 64 | Azenta, Inc. (subject), Section 10b CEO total | DEF 14A | 2025-12-18 | 0001140361-25-046064 | CEO total compensation as printed in Azenta, Inc.'s own proxy. As printed: 10,371,414. Filing ↗machine: r2 · c22 · span 1247118–1247129 |
| 65 | Maravai LifeSciences Holdings Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001823239-26-000014 | CEO total compensation as printed in Maravai LifeSciences Holdings Inc.'s own proxy. As printed: 10,129,708. Filing ↗machine: t21 · r3 · c20 · span 502645–502655 |
| 66 | Neogen Corporation, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001077183-26-000014 | CEO total compensation as printed in Neogen Corporation's own proxy. As printed: 9,127,092. Filing ↗machine: r2 · c45 · span 869460–869469 |
| 67 | Neogen Corporation, Section 10b CEO total | DEF 14A | 2026-08-21 | 0001193125-26-360742 | CEO total compensation as printed in Neogen Corporation's own proxy. As printed: 8,693,916. Filing ↗machine: span 1672214–1672223 |
| 68 | Guardant Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187403 | CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. Filing ↗machine: r7 · c31 · span 773149–773158 |
| 69 | Bio-Techne Corporation, Section 10b CEO total | DEF 14A | 2025-09-19 | 0001308179-25-000599 | CEO total compensation as printed in Bio-Techne Corporation's own proxy. As printed: 8,151,181. Filing ↗machine: span 792074–792083 |
| 70 | Veracyte, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001384101-26-000021 | CEO total compensation as printed in Veracyte, Inc.'s own proxy. As printed: 7,421,877. Filing ↗machine: r4 · c27 · span 855413–855422 |
| 71 | Tandem Diabetes Care, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001438133-26-000034 | CEO total compensation as printed in Tandem Diabetes Care, Inc.'s own proxy. As printed: 6,858,503. Filing ↗machine: r3 · c27 · span 866963–866972 |
| 72 | Certara, Inc., Section 10b CEO total | DEF 14A | 2026-04-03 | 0001104659-26-039372 | CEO total compensation as printed in Certara, Inc.'s own proxy. As printed: 6,491,387. Filing ↗machine: r1 · c42 · span 883232–883241 |
| 73 | 10x Genomics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001628280-26-027201 | CEO total compensation as printed in 10x Genomics, Inc.'s own proxy. As printed: 6,329,244. Filing ↗machine: r3 · c48 · span 583283–583292 |
| 74 | Fulgent Genetics, Inc., Section 10b CEO total | DEF 14A | 2026-03-31 | 0001674930-26-000020 | CEO total compensation as printed in Fulgent Genetics, Inc.'s own proxy. As printed: 6,207,000. Filing ↗machine: r3 · c22 · span 533279–533288 |
| 75 | Repligen Corporation, Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-140115 | CEO total compensation as printed in Repligen Corporation's own proxy. As printed: 6,114,771. Filing ↗machine: t16 · r4 · c2 · span 577065–577074 |
| 76 | NeoGenomics, Inc., Section 10b CEO total | DEF 14A | 2023-03-29 | 0001628280-23-009712 | CEO total compensation as printed in NeoGenomics, Inc.'s own proxy. As printed: 5,933,500. Filing ↗machine: r2 · c42 · span 406619–406628 |
| 77 | Myriad Genetics, Inc., Section 10b CEO total | DEF 14A | 2026-04-14 | 0000899923-26-000031 | CEO total compensation as printed in Myriad Genetics, Inc.'s own proxy. As printed: 5,686,740. Filing ↗machine: r2 · c24 · span 792986–792996 |
| 78 | Cytek Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001140361-26-017479 | CEO total compensation as printed in Cytek Biosciences, Inc.'s own proxy. As printed: 5,120,061. Filing ↗machine: r2 · c21 · span 561243–561252 |
| 79 | Cryoport, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001140361-26-016129 | CEO total compensation as printed in Cryoport, Inc.'s own proxy. As printed: 2,375,524. Filing ↗machine: t277 · r2 · c22 · span 1285130–1285139 |
| 80 | Section 10a, Fulgent Genetics, Inc. reciprocity | DEF 14A | — | 0001674930-26-000020 | Fulgent Genetics, Inc.'s most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 81 | Section 10a, Neogen Corporation reciprocity | DEF 14A | — | 0001193125-26-360742 | Neogen Corporation names Azenta, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 82 | Section 10a, Veracyte, Inc. reciprocity | DEF 14A | — | 0001384101-26-000021 | Veracyte, Inc.'s most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 83 | Section 10a, Cytek Biosciences, Inc. reciprocity | DEF 14A | — | 0001140361-26-017479 | Cytek Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 84 | Section 10a, Tandem Diabetes Care, Inc. reciprocity | DEF 14A | — | 0001438133-26-000034 | Tandem Diabetes Care, Inc.'s most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 85 | Section 10a, 10x Genomics, Inc. reciprocity | DEF 14A | — | 0001628280-26-027201 | 10x Genomics, Inc. names Azenta, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 86 | Section 10a, Medpace Holdings, Inc. reciprocity | DEF 14A | — | 0001668397-26-000012 | Medpace Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 87 | Section 10a, Repligen Corporation reciprocity | DEF 14A | — | 0001193125-26-140115 | Repligen Corporation names Azenta, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 88 | Section 10a, Certara, Inc. reciprocity | DEF 14A | — | 0001104659-26-039372 | Certara, Inc.'s most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 89 | Section 10a, Natera, Inc. reciprocity | DEF 14A | — | 0001104659-26-047770 | Natera, Inc.'s most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 90 | Section 10a, Haemonetics Corporation reciprocity | DEF 14A | — | 0000313143-26-000074 | Haemonetics Corporation names Azenta, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 91 | Section 10a, Maravai LifeSciences Holdings Inc. reciprocity | DEF 14A | — | 0001823239-26-000014 | Maravai LifeSciences Holdings Inc. names Azenta, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 92 | Section 10a, Guardant Health, Inc. reciprocity | DEF 14A | — | 0001193125-26-187403 | Guardant Health, Inc.'s most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 93 | Section 10a, NeoGenomics, Inc. reciprocity | DEF 14A | — | 0001628280-23-009712 | NeoGenomics, Inc.'s most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 94 | Section 10a, Neogen Corporation reciprocity | DEF 14A | — | 0001077183-26-000014 | Neogen Corporation's most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
| 95 | Section 10a, Bio-Techne Corporation reciprocity | DEF 14A | — | 0001308179-25-000599 | Bio-Techne Corporation's most recent proxy was read; its disclosed peer group does not include Azenta, Inc.. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the Azenta, Inc. Executive Compensation Report
$1,500